These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35004241)

  • 21. Lurbinectedin for the treatment of small cell lung cancer.
    Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
    Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of Systemic Inflammation Parameters and Serum SLFN11 in Small Cell Lung Cancer-A Prospective Pilot Study.
    Simić I; Guzonjić A; Kotur Stevuljević J; Ćeriman Krstić V; Samardžić N; Savić Vujović K; Jovanović D
    Biomedicines; 2024 Apr; 12(5):. PubMed ID: 38790938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
    Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
    Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
    Coussy F; El-Botty R; Château-Joubert S; Dahmani A; Montaudon E; Leboucher S; Morisset L; Painsec P; Sourd L; Huguet L; Nemati F; Servely JL; Larcher T; Vacher S; Briaux A; Reyes C; La Rosa P; Lucotte G; Popova T; Foidart P; Sounni NE; Noel A; Decaudin D; Fuhrmann L; Salomon A; Reyal F; Mueller C; Ter Brugge P; Jonkers J; Poupon MF; Stern MH; Bièche I; Pommier Y; Marangoni E
    Sci Transl Med; 2020 Feb; 12(531):. PubMed ID: 32075943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer.
    Patel S; Petty WJ; Sands JM
    Ther Adv Med Oncol; 2021; 13():17588359211020529. PubMed ID: 34104228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses.
    Knelson EH; Patel SA; Sands JM
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33578789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer.
    Tummala T; Sevilla Uruchurtu AS; Cruz A; Huntington KE; George A; Liguori NR; Zhang L; Zhou L; Abbas AE; Azzoli CG; El-Deiry WS
    Curr Oncol; 2023 Oct; 30(11):9611-9626. PubMed ID: 37999116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SLFN11 Blocks Stressed Replication Forks Independently of ATR.
    Murai J; Tang SW; Leo E; Baechler SA; Redon CE; Zhang H; Al Abo M; Rajapakse VN; Nakamura E; Jenkins LMM; Aladjem MI; Pommier Y
    Mol Cell; 2018 Feb; 69(3):371-384.e6. PubMed ID: 29395061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Schlafen11 Expression Is Associated With the Antitumor Activity of Trabectedin in Human Sarcoma Cell Lines.
    Iwasaki J; Komori T; Nakagawa F; Nagase H; Uchida J; Matsuo K; Uto Y
    Anticancer Res; 2019 Jul; 39(7):3553-3563. PubMed ID: 31262879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
    Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE
    Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lurbinectedin in small cell lung cancer.
    Manzo A; Sforza V; Carillio G; Palumbo G; Montanino A; Sandomenico C; Costanzo R; Esposito G; Laudato F; Mercadante E; La Manna C; Muto P; Totaro G; De Cecio R; Picone C; Piccirillo MC; Pascarella G; Normanno N; Morabito A
    Front Oncol; 2022; 12():932105. PubMed ID: 36110944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
    Manavella DD; McNamara B; Harold J; Bellone S; Hartwich TMP; Yang-Hartwich Y; Mutlu L; Zipponi M; Demirkiran C; Verzosa MS; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Dottino PR; Choi J; Alexandrov LB; Buza N; Hui P; Santin AD
    Gynecol Oncol; 2023 Feb; 169():98-105. PubMed ID: 36525930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
    Desai A; Smith CJ; Ashara Y; Orme JJ; Zanwar S; Potter A; Hocum C; Moffett JN; Schwecke AJ; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Molina J; Dimou A; Mansfield AS; Parikh K; Leventakos K
    Clin Lung Cancer; 2023 Dec; 24(8):689-695.e1. PubMed ID: 37880074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
    Cardnell RJ; Feng Y; Diao L; Fan YH; Masrorpour F; Wang J; Shen Y; Mills GB; Minna JD; Heymach JV; Byers LA
    Clin Cancer Res; 2013 Nov; 19(22):6322-8. PubMed ID: 24077350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic silencing schlafen-11 sensitizes esophageal cancer to ATM inhibitor.
    Zhou J; Zhang MY; Gao AA; Zhu C; He T; Herman JG; Guo MZ
    World J Gastrointest Oncol; 2024 May; 16(5):2060-2073. PubMed ID: 38764821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms.
    Southgate HED; Chen L; Tweddle DA; Curtin NJ
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32354033
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeting ATR Kinase as a Strategy for Canine Lymphoma and Leukaemia Treatment.
    Henklewska M; Pawlak A; Obmińska-Mrukowicz B
    Vet Comp Oncol; 2024 Dec; 22(4):602-612. PubMed ID: 39300906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243.
    Murai Y; Jo U; Murai J; Jenkins LM; Huang SN; Chakka S; Chen L; Cheng K; Fukuda S; Takebe N; Pommier Y
    Cancer Res; 2021 Jun; 81(11):3067-3078. PubMed ID: 33863777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.